Weekly Notables

The FDA is seeking insights into delays in developing personalized cell and gene therapies. Big pharmaceutical companies have endorsed a lung cancer awareness campaign during UNGA week and several commitments were announced to tuberculosis response efforts. Europe is preparing for long-term tenders for mRNA COVID vaccines, and the urgency of addressing Alzheimer's disease was emphasized. In marketing, TikTok's algorithm and audience appeal are attracting pharma into the platform. In policy news, the European Parliament both welcomes and criticizes proposed pharmaceutical packages. This and more news below.

Efforts are being made to reestablish vaccine leadership in the EU, but climate change is posing challenges to the fight against AIDS, TB, and malaria. In the pharmaceutical and healthcare sectors, companies like Novartis and Gilead Sciences are using innovative approaches to raise awareness, while the FDA is proposing changes to medical device approval pathways.

Roche improves its phase 3 biotech pipeline. Real-world data boosts healthcare engagement. Novartis rebrands its research labs. Big Pharma battles the Biden Administration. Concerns arise about the Inflation Reduction Act's impact on new medicines. CMS assesses pharmaceutical innovation. The UK rejoins the EU's Horizon science scheme, and Alzheimer's discourse is being reframed.

In the healthcare spotlight, Carl June stands as a pioneer with his groundbreaking work on a 'universal CAR-T' therapy, potentially reshaping cancer treatment. Simultaneously, an industry-backed film sheds light on the looming global threat of antimicrobial resistance, underlining the urgent need for collaborative efforts to address this crisis. Meanwhile, Novo Nordisk's ascent to Europe's most valuable pharmaceutical company demonstrates the dynamic nature of healthcare markets, signifying significant shifts in industry value.

From the challenge of tackling the 'silent pandemic' of superbugs, to Pharma navigating through an 'age of uncertainty' with hurdles like regulatory challenges, patent cliffs, and Medicare's drug pricing negotiations. Insights on the Innovative Medicines Fund critique, orphan drugs' unique dynamics, and the breakthrough potential of Y chromosome sequencing captivate the field.

Amidst the biotech landscape, widespread layoffs persist, prompting reflections on their implications for the industry's future. Efforts to address diversity in medical illustrations gain momentum through a Nigerian doctor's initiative. Google emerges as a burgeoning force in healthcare innovation...

The UK's 'Golden Triangle' is set to expand with new lab and manufacturing facilities as a new £1 billion life science campus gains approval for construction. Former biotech leader Vivek Ramaswamy's emergence in U.S. presidential polls raises questions about his impact on the life sciences sector...

The biotech venture capital sector shows potential growth following one firm's crisis-to-profit success. Healthcare practitioners' attention is drawn to non-physical health side effects, while a new study reveals a 50% global risk of developing mental health conditions by age 75...

The biotech sector faces a crisis in gene therapy, with leading experts seeking solutions. The FDA's accelerated approval process is likely to focus on more rare disease drugs. Early-stage biopharma funding is expected to drop 40% this year, while pharma deals aim for innovation and first-in-class drugs...